NCT07081555
A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer
At risk: Primary completion moved 5 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 10 words Show 4 more changesShow less
- Primary completion pushed from Jan 1, 2027 to Jun 1, 2027
- Study sites: 3 to 4
- Secondary endpoints: details revised at 2 of 3 entries
- Study description revised
- Notable Start date: Aug 1, 2025 to Oct 6, 2025v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Treatment emergent adverse events
Timeframe: From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43
Dose Limiting Toxicities
Timeframe: From baseline to the end-of-trial visit, for part A Day 29 and for part B Day 43
Secondary (3)
Absorbed dose in gray (Gy) per organ and selected tumors
Absorbed dose coefficient (Gy/GBq) per organ and selected tumors
Normalized whole-body effective dose (millisieverts [mSv]/MBq)
Arms and interventions
Part AExperimental
\[177Lu\]Lu-ABY-271
Part B - Cohort 1Experimental
\[177Lu\]Lu-ABY-271 with protein mass dose A
Part B - Cohort 2Experimental
\[177Lu\]Lu-ABY-271 with protein mass dose B
Part B - Cohort 3Experimental
\[177Lu\]Lu-ABY-271 with Protein mass dose C
Drugs: [177Lu]Lu-ABY-271
Sites
4 sites in 2 countries
Sweden 3, Norway 1